多巴胺受体激动剂普拉克索治疗帕金森病的临床效果及其安全性分析

发布时间：2018-03-24 04:06

  本文选题：帕金森病　切入点：普拉克索　出处：《中国医药指南》2016年35期

【摘要】：目的探讨帕金森病患者经多巴胺受体激动剂普拉克索治疗的临床效果及安全性。方法回顾性分析我院2013年5月至2015年5月收治的60例帕金森病患者的临床资料,60例帕金森病患者随机划分为观察组与对照组,两组各30例。观察组30例患者给予巴胺受体激动剂普拉克索治疗,对照组30例患者给予帕罗西汀联合美多芭治疗。选取汉密顿抑郁量表、统一帕金森评定量表的第Ⅲ部分进行疗效评定,每4周评定一次临床治疗效果;选取不良反应量表于第12周末对治疗安全性进行评定。对比观察组患者与对照组患者临床治疗效果及安全性。结果观察组与对照组第4周末、第8周末的HAMD评分、UPDRSⅢ总分无明显差异,不具备统计学意义(P0.05);观察组第12周末HAMD评分、UPDRSⅢ总分明显优于对照组,两组差异具有统计学意义(P0.05);观察组不良反应发生率明显低于对照组,两组差异具有统计学意义(P0.05)。结论帕金森病患者经多巴胺受体激动剂普拉克索治疗的临床效果十分显著,安全性好,值得在临床治疗中推广应用。
[Abstract]:Objective to investigate the clinical efficacy and safety of Parkinson's disease treated with dopamine receptor agonist Praxol. Methods the clinical data of 60 patients with Parkinson's disease from May 2013 to May 2015 were retrospectively analyzed. Patients with Parkinson's disease were randomly divided into observation group and control group. There were 30 cases in each group. 30 patients in the observation group were treated with praquisol, and 30 patients in the control group were treated with paroxetine combined with medoba. The curative effect was evaluated in the third part of the unified Parkinson's scale, and the clinical treatment effect was evaluated every 4 weeks. Adverse reaction scale was selected to evaluate the safety of the treatment at the end of the 12th week. The clinical efficacy and safety of the patients in the observation group and the control group were compared. Results at the end of the 4th week, the patients in the observation group and the control group were assessed. At the end of the 8th week, there was no significant difference in the total score of HAMD 鈪，

本文编号：1656618